New insider activity at Merck & Company ( (MRK) ) has taken place on February 12, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Merck & Company’s Chief Marketing Officer, Chirfi Guindo, has recently offloaded a substantial portion of company stock, selling 10,000 shares in a transaction valued at $1,214,500. This insider sale highlights a notable move by a key executive at the pharmaceutical giant, drawing attention from investors who closely watch leadership trading activity for potential signals about the company’s outlook and stock performance.
Spark’s Take on MRK Stock
According to Spark, TipRanks’ AI Analyst, MRK is a Outperform.
MRK scores well due to strong underlying financial performance and a technically supported uptrend, reinforced by a reasonable P/E and solid dividend yield. The main offset is earnings-call-driven near-term pressure from vaccine softness, pricing/generic headwinds, and the sizable one-time acquisition charge weighing on reported 2026 results.
To see Spark’s full report on MRK stock, click here.
More about Merck & Company
YTD Price Performance: 11.77%
Average Trading Volume: 14,885,714
Technical Sentiment Signal: Buy
Current Market Cap: $290.8B